# AEMD — Aethlon Medical Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** AEMD  
**Sources:** 18  
**Published:** 2026-10-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-aemd-aethlon-medical-inc-catalysts-narrative-risks-5873

---

## Overview

Aethlon Medical, Inc. (Nasdaq: AEMD) is a San Diego–based, clinical-stage medical device company centered on the Hemopurifier, an investigational extracorporeal device designed to remove tumor-derived extracellular vesicles and enveloped viruses from circulation [[2]](https://www.nasdaq.com/press-release/aethlon-medical-reports-q1-fiscal-2027-results-and-progress-hemopurifierr-program). As of the Oct 2, 2026 close, the stock traded around $6.45 on a tiny market capitalization (roughly $4.5–4.8M) [[11]](https://www.marketbeat.com/stocks/NASDAQ/AEMD/)[[12]](https://tickernerd.com/stock/aemd-forecast/)[[13]](https://wallstsmart.com/stock/AEMD). The single most important recent development is an announced all-stock merger with North Immunology that will, upon closing, change the company's identity and ticker.

## Key Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-aemd-aethlon-medical-inc-catalysts-narrative-risks-5873 (free to sign up)._
